As per the American Academy of Ophthalmology report, smoking leads to major ocular pains and eye diseases, including Age-related macular degeneration, diabetic retinopathy, dry eyes, cataracts and optic nerve problems. Smoking increases the chances of damage in the eye’s optic nerve, which results in clouding of the lens, glaucoma, and dry eye syndromes. Hence, increase in the cases of eye diseases will expected to enhance the market growth.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-ocular-pain-market
Data Bridge Market Research analyses a growth rate in the Global Ocular Pain Market in the forecast period 2022-2029. The expected CAGR of global ocular pain market is tend to be around 8% in the mentioned forecast period. Increasing healthcare expenditure and growing geriatric population and will likely to increase the growth of the global ocular pain market.
Rising prevalence of ophthalmic disorders and ocular pains is expected to drive the market's growth rate
Ophthalmic disorders are the major cause of ocular and orbital pain in an eye. Ocular pains occur over the surface of eyes, such as burning, scratching, or itching sensation due to various reasons, including infection, irritation from foreign objects, or trauma. Mostly the person’s eye lashes, piece of dirt, dust, smoke and some harsh eye cosmetics leads to ocular pain, watery eyes , redness and among others. WebMD LLC reported that the In January 2019 prevalence from 8% has increased to 10% of every eye-related emergency care visit. These factors state that this is the major driver for the market's growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014- 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Specialty Clinics, Others),
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Aerie Pharmaceuticals, Inc. (U.S.), Bausch Health (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Alcon (Switzerland), Bayer AG (Germany), Carl Zeiss Meditec AG (Germany), HumanOptics Holding AG (Germany), Sun Pharmaceuticals Industries Ltd. (India), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S.), Bausch Health Companies Inc. (U.S.), Ocular Therapeutix, Inc. (U.S.), IACTA Pharmaceuticals, Inc (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The ocular pain market is segmented on the basis of disease type, type, application, route of administration, drug type, distribution channel and end-user.
- On the basis of disease type, the global ocular pain market is segmented into ocular pain with eye diseases and ocular pain without eye diseases.
The ocular pain with eye diseases segment of disease type segment is anticipated to dominate the ocular pain market
The ocular pain with eye diseases segment is dominating the global ocular pain market with a market share of 73.73% because of increasing prevalence of ophthalmic disorders such as sty, glaucoma, conjunctivitis, and many more in developed and developing countries globally.
- On the basis of type, the global ocular pain market is segmented into diagnosis and treatment. The diagnosis segment is dominating the global ocular pain market with a market share of 65.46% because of increasing research and development activities specified for diagnosis.
- On the basis of application, the global ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. The glaucoma segment is dominating the global ocular pain market with a market share of 29.99% because of increasing cases of glaucoma with severe ocular pain in last few years globally estimated.
- On the basis of route of administration, the global ocular pain market is segmented into topical, periocular, intraocular, oral, and others. The topical segment is dominating the global ocular pain market with a market share of 82.10% because most mild ocular pain is cured primarily with eye drop solutions, ointments and gels.
- On the basis of drug type, the global ocular pain market is segmented into prescription and over the counter. The prescription segment is dominating the global ocular pain market with a market share of 88.58% because of increasing awareness among people regarding eye-related diseases and growing stringent rules by regulatory authority to mandate prescription for main topical ophthalmic solutions.
- On the basis of distribution channel, the global ocular pain market is segmented into hospital pharmacy, retail pharmacy, others. The direct tender segment is dominating the global ocular pain market with a market share of 34.86% because of increasing number of contacts for the supply of ocular pain products.
- On the basis of end-users, the global ocular pain market is segmented into hospitals, specialty clinics, home healthcare settings, ophthalmology centers, ambulatory surgical centers, and others.
The hospitals segment of end-users segment is anticipated to distribution channel the ocular pain market
The hospitals segment is dominating the global ocular pain market with a market share of 28.24% due to rising disposable income and healthcare expenditure in developing countries and increasing government funds provided for constructions of hospital with eye care sections.
Major Players
Data Bridge Market Research recognizes the following companies as the major ocular pain market players in ocular pain market Aerie Pharmaceuticals, Inc. (U.S.), Bausch Health (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Alcon (Switzerland), Bayer AG (Germany), Carl Zeiss Meditec AG (Germany), HumanOptics Holding AG (Germany)
Market Development
- In 2020, Bausch & Lomb Incorporated announced their website's launch of Biotrue Micellar Eyelid Cleansing Wipes and Biotrue Hydration Boost Lubricant Eye Drops. These products are preservative-free and also provide best therapeutic options for dry eyes. Thereby, this improved their revenue for the market.
- In 2020, Bausch & Lomb Incorporated announced that they successfully acquired options for buying all the ophthalmology assets of Allegro Ophthalmic, LLC, which is a private biopharmaceutical company employed for ocular diseases. This acquisition aided the company in increasing their revenue over the market.
Regional Analysis
Geographically, the countries covered in the ocular pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
Asia-Pacific is the dominant region in ocular pain market during the forecast period 2022 to 2029
Asia-Pacific dominates the ocular pain market due to the presence of highest number of geriatric and vulnerable populations in this region. Furthermore, surge in investments in the healthcare sector will further enhance the market growth in this region.
North America is estimated to be the fastest-growing region in ocular pain market the forecast period 2022 to 2029
North America is expected to grow from 2022 to 2029 because of growing cases of ophthalmic disorders in this region. Additionally, the growing adoption of government authorities' policies, initiatives and programs will further boost this region's market growth.
For more detailed information about ocular pain market report, click here – https://www.databridgemarketresearch.com/reports/global-ocular-pain-market
